Positive News SentimentPositive NewsNASDAQ:CTKB Cytek Biosciences (CTKB) Stock Price, News & Analysis $5.30 -0.14 (-2.57%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$5.26▼$5.4850-Day Range$5.09▼$6.7352-Week Range$3.80▼$9.87Volume578,273 shsAverage Volume684,335 shsMarket Capitalization$695.75 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cytek Biosciences alerts: Email Address Cytek Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside60.4% Upside$8.50 Price TargetShort InterestHealthy3.84% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.11) to $0.03 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.65 out of 5 starsMedical Sector406th out of 910 stocksAnalytical Instruments Industry14th out of 26 stocks 3.4 Analyst's Opinion Consensus RatingCytek Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCytek Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Cytek Biosciences' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.84% of the float of Cytek Biosciences has been sold short.Short Interest Ratio / Days to CoverCytek Biosciences has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Cytek Biosciences has recently decreased by 16.27%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytek Biosciences does not currently pay a dividend.Dividend GrowthCytek Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTKB. Previous Next 2.7 News and Social Media Coverage News SentimentCytek Biosciences has a news sentiment score of 1.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cytek Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for CTKB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cytek Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytek Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of Cytek Biosciences is held by insiders.Percentage Held by Institutions69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cytek Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytek Biosciences are expected to grow in the coming year, from ($0.11) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytek Biosciences is -58.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytek Biosciences is -58.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytek Biosciences has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cytek Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] About Cytek Biosciences Stock (NASDAQ:CTKB)Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.Read More CTKB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTKB Stock News HeadlinesAugust 21, 2024 | globenewswire.comCytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing FacilityAugust 7, 2024 | markets.businessinsider.comCytek Biosciences: Poised for Turnaround Despite Q2 Setbacks, Analyst Maintains Buy RatingSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 6, 2024 | markets.businessinsider.comCytek Biosciences Reports Second Quarter 2024 Financial ResultsAugust 5, 2024 | markets.businessinsider.comCytek Biosciences, earnings: here's what to expectJuly 30, 2024 | globenewswire.comCytek® Biosciences Automates Panel Design with New Intelligent AlgorithmJuly 22, 2024 | finance.yahoo.comCytek Biosciences, Inc. (NASDAQ:CTKB) is a favorite amongst institutional investors who own 51%May 30, 2024 | globenewswire.comCytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare ConferenceSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.May 29, 2024 | finanznachrichten.deCytek Biosciences, Inc.: 1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek Biosciences Approved for Clinical Use in ChinaMay 28, 2024 | globenewswire.com1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in ChinaMay 20, 2024 | globenewswire.comCytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis SystemsMay 13, 2024 | finance.yahoo.comCytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comCytek Biosciences Inc (CTKB) Q1 2024 Earnings: Revenue Surges, Yet Net Loss PersistsMay 9, 2024 | markets.businessinsider.comCytek Biosciences, Inc. Reports Q1 Loss, Tops Revenue EstimatesMay 9, 2024 | finanznachrichten.deCytek Biosciences, Inc.: Cytek Biosciences Reports First Quarter 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comCytek Biosciences Inc (CTKB) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...May 8, 2024 | investorplace.comCTKB Stock Earnings: Cytek Biosciences Misses EPS, Beats Revenue for Q1 2024See More Headlines Receive CTKB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:CTKB CUSIPN/A CIK1831915 Webwww.cytekdev.com Phone877-922-9835FaxN/AEmployees500Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$10.00 Low Stock Price Target$7.00 Potential Upside/Downside+60.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,150,000.00 Net Margins-8.88% Pretax Margin-8.22% Return on Equity-3.75% Return on Assets-3.00% Debt Debt-to-Equity RatioN/A Current Ratio7.33 Quick Ratio6.38 Sales & Book Value Annual Sales$197.71 million Price / Sales3.52 Cash Flow$0.02 per share Price / Cash Flow227.57 Book Value$2.96 per share Price / Book1.79Miscellaneous Outstanding Shares131,273,000Free Float118,671,000Market Cap$695.75 million OptionableOptionable Beta1.31 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Wenbin Jiang Ph.D. (Age 60)President, CEO & Chairman of the Board Comp: $964.21kDr. Ming Yan Ph.D. (Age 61)CTO & Director Comp: $616.26kMs. Valerie T. Barnett J.D. (Age 48)Chief Legal Officer Comp: $535.98kMr. William D. McCombe (Age 66)Chief Financial Officer Mr. Chris Williams (Age 55)Chief Operating Officer Dr. Allen B. Poirson Ph.D. (Age 64)Senior Vice President of Business & Corporate Development Dr. Philippe Busque Ph.D.Senior Vice President of Global Sales & ServicesMr. Patrik Sebastian Jeanmonod (Age 57)Head of Corporate Development Analytics Comp: $412.54kMore ExecutivesKey CompetitorsAllogene TherapeuticsNASDAQ:ALLOValnevaNASDAQ:VALNProthenaNASDAQ:PRTAInstil BioNASDAQ:TILMirion TechnologiesNYSE:MIRView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckyBought 36,603 shares on 8/26/2024Ownership: 0.113%Algert Global LLCBought 168,665 shares on 8/16/2024Ownership: 0.225%The Manufacturers Life Insurance Company Bought 2,460 shares on 8/15/2024Ownership: 0.049%AQR Capital Management LLCBought 40,240 shares on 8/15/2024Ownership: 0.046%Dark Forest Capital Management LPBought 9,711 shares on 8/15/2024Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions CTKB Stock Analysis - Frequently Asked Questions How have CTKB shares performed this year? Cytek Biosciences' stock was trading at $9.12 on January 1st, 2024. Since then, CTKB shares have decreased by 41.9% and is now trading at $5.30. View the best growth stocks for 2024 here. How were Cytek Biosciences' earnings last quarter? Cytek Biosciences, Inc. (NASDAQ:CTKB) announced its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.05. The business earned $46.62 million during the quarter, compared to analysts' expectations of $49.02 million. Cytek Biosciences had a negative net margin of 8.88% and a negative trailing twelve-month return on equity of 3.75%. When did Cytek Biosciences IPO? Cytek Biosciences (CTKB) raised $248 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 14,564,635 shares at $16.00-$18.00 per share. Who are Cytek Biosciences' major shareholders? Top institutional shareholders of Cytek Biosciences include Dimensional Fund Advisors LP (1.12%), Millennium Management LLC (0.72%), Bank of New York Mellon Corp (0.61%) and Principal Financial Group Inc. (0.37%). Insiders that own company stock include Ming Yan, Wenbin Jiang, Patrik Jeanmonod, Jack Ball and Ra Capital Management, LP. View institutional ownership trends. How do I buy shares of Cytek Biosciences? Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTKB) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.